I'll put PTX's MC between that of Imugene (MC about $100m) and Viralytics (MC about $500m), implying a price target between $0.5 to $2.5, as market will immediately compare against those two listco since they are all in oncology with Paul Hopper sitting on all their board.
Heard that Bistrol Myers Squibb may also give a competing bid after Merck for Viralytics. This is good for PTX too as the scene for M&A and licensing is getting hot. One of them may big for PTX or Imugene when it fails to grab Viralytics which MC should go up further if the bidding war starts.
There is very little free float and once price starts to jump, it will move very sharply to desired sp very quickly. So continue to hold tightly and add bit by bit for a life changing stock for all the holders/buyers in 2018.
PTX Price at posting:
11.5¢ Sentiment: Buy Disclosure: Held
